Lilly’s Zyprexa Protection Strategy: Stress Efficacy, Institutional Market
Executive Summary
Lilly will protect Zyprexa's market share from generic competition by emphasizing the atypical antipsychotic's efficacy and by focusing on the institutional, urgent-need patient market, President and incoming CEO John Lechleiter said during the company's Jan. 29 sales and earnings call
You may also be interested in...
As Risperdal Goes Generic, Antipsychotics Seek To Differentiate Themselves
Johnson & Johnson and other manufacturers of atypical antipsychotics face erosion of their market share with FDA's approval of the first generic version of J&J's Risperdal (risperidone). But they may ward off competition by emphasizing the differences between their products and the first generic among the newer antipsychotics
As Risperdal Goes Generic, Antipsychotics Seek To Differentiate Themselves
Johnson & Johnson and other manufacturers of atypical antipsychotics face erosion of their market share with FDA's approval of the first generic version of J&J's Risperdal (risperidone). But they may ward off competition by emphasizing the differences between their products and the first generic among the newer antipsychotics
Diabetes Draft Guidance May Require Extended Trial Length, Participation
A long-awaited diabetes draft guidance from FDA may result in longer and larger clinical trials, but does not significantly alter the development landscape since it re-affirms the agency's faith in a long-used surrogate marker and the technique of post-market outcomes assessment